Insider Selling: Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) Major Shareholder Sells 281,408 Shares of Stock

Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) major shareholder Orbimed Advisors Llc sold 281,408 shares of Bitwise MARA Option Income Strategy ETF stock in a transaction on Monday, June 15th. The shares were sold at an average price of $45.02, for a total value of $12,668,988.16. Following the sale, the insider directly owned 245,728 shares of the company’s stock, valued at approximately $11,062,674.56. This trade represents a 53.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Bitwise MARA Option Income Strategy ETF Stock Performance

NYSEARCA IMRA traded down $0.33 on Wednesday, reaching $17.02. 446 shares of the stock traded hands, compared to its average volume of 5,461. The company has a fifty day moving average price of $16.35 and a 200-day moving average price of $15.83. The company has a market cap of $3.23 million, a price-to-earnings ratio of 340.40 and a beta of 2.88. Bitwise MARA Option Income Strategy ETF has a 12 month low of $11.99 and a 12 month high of $54.94.

About Bitwise MARA Option Income Strategy ETF

IMARA Inc, a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2–related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas.